We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Mifepristone in Children With Refractory Cushing's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01925092
Recruitment Status : Withdrawn (Lack of enrollment)
First Posted : August 19, 2013
Last Update Posted : August 4, 2014
Information provided by (Responsible Party):

Study Description
Brief Summary:
Study objectives are to obtain safety, pharmacokinetic, and pharmacodynamic data on the effect of mifepristone on glucose metabolism, body weight and the growth-hormone-IGF in children with refractory Cushing's disease.

Condition or disease Intervention/treatment Phase
Cushing's Disease Drug: mifepristone Phase 3

Detailed Description:
The study is being done to examine the effects of a medication called mifepristone in children with Cushing's disease. Since a child's body may absorb and use mifepristone in a different way than adults, it is important to have information about the amount of mifepristone to give children and what will happen to it. Mifepristone has been FDA approved for use only in adults with Cushing's syndrome, and it is important to learn if mifepristone improves the symptoms and signs of Cushing's disease in children. The study is limited to children with Cushing's syndrome due to a pituitary tumor (Cushing's disease) and will not enroll children with Cushing's syndrome due to other causes. The study will investigate how children's bodies absorb and process mifepristone, how it works in children and what effect it has on the use of sugar in the body, on the child's weight and on growth hormone. An important part of the study is to evaluate the side effects of mifepristone in children.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease
Study Start Date : August 2013
Estimated Primary Completion Date : December 2016

Arms and Interventions

Arm Intervention/treatment
Experimental: mifepristone
Daily doses of mifepristone over 84 days.
Drug: mifepristone
Other Name: Korlym

Outcome Measures

Primary Outcome Measures :
  1. Adverse events [ Time Frame: collected during the12 week study and 4 week follow-up period; up to 16 weeks total. ]
    Patients who have received at least 1 dose of mifepristone will be included in the safety evaluations.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   6 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females 6-17 years at informed consent
  • Active Cushing's disease as demonstrated by the following:
  • 24 hour Urinary Free Cortisol greater than the upper limit of normal for age on two urine collections during screening and
  • midnight serum cortisol >4.4 mcg/dL (mean of two determinations on a single day at 2330 and 2400 during screening)
  • Previous trans-sphenoidal surgery (TSS) for ACTH secreting pituitary tumor at least 3 months prior to screening
  • Increased body weight defined by BMI Z-score of 1.5 or above
  • Able to provide consent/assent
  • Able to swallow study drug tablets (not crushed or split)
  • Willing to use non-hormonal method of contraception in patients of reproductive potential
  • Primary health care provider in home location

Exclusion Criteria:

  • Hypercortisolism not due to Cushing's disease.
  • Type 1 diabetes mellitus
  • HbA1c ≥9.5% at Screening
  • Body weight <25 kg
  • Use of certain medications that are CYP3A substrates with narrow therapeutic ranges, such as simvastatin, lovastatin, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus during the 4 weeks prior to starting study drug. Use of these medications is also prohibited until 2 weeks after end of dosing.
  • Use of certain medications that are strong CYP3A inhibitors such as itraconazole, nefazodone, ritonavir, nelfinavir, indinavir, atazanavir, amprenavir, fosamprenavir, boceprevir, clarithromycin, conivaptan, lopinavir, mibefradil, posaconazole, saquinavir, telaprevir, telithromycin, and voriconazole during the 2 weeks prior to starting study drug. Use of these medications is also prohibited until 2 weeks after end of dosing. Grapefruit and grapefruit juice, as well as grapefruit-related fruits and their juice (e.g. Seville oranges, pomelos), are prohibited during this time frame.
  • Use of certain medications that are strong inducers of CYP3A such as rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, St. John's wort during the 2 weeks prior to starting study drug. Use of these medications is also prohibited until 2 weeks after end of dosing.
  • Use of medications used to treat hypercortisolism from the duration indicated below prior to Day 1. Use of the medications is also prohibited until after the end of study 4 week follow up visit.
  • steroidogenesis inhibitors such as ketoconazole, metyrapone: 4 weeks
  • cabergoline, bromocriptine, somatostatin analogs such as octreotide, lanreotide, pasireotide long acting formulations: 8 weeks (immediate release formulations: 2 weeks)
  • mitotane: 8 weeks
  • Use of systemic glucocorticoid medications beginning 1 month prior to screening or anticipated use of these medications except for the treatment of adrenal insufficiency. Use of glucocorticoid medications is prohibited during the study until after the end of study 4 week study visit.
  • Inflammatory, rheumatological, proliferative or other disorder(s) that would be anticipated to worsen with glucocorticoid blockade (e.g. inflammatory bowel disease, rheumatoid arthritis, psoriasis, etc.).
  • Uncontrolled hypo- or hyperthyroidism.
  • Uncorrected hypokalemia (<3.5 mEq/L). The screening period may be used to correct hypokalemia prior to starting study drug. Use of potassium and/or mineralocorticoid antagonists is permitted during the study.
  • QTc ≥450 msec on Screening electrocardiogram
  • Unexplained vaginal bleeding in females and/or any history of endometrial pathology.
  • Positive pregnancy test in females.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01925092

United States, Maryland
National Institute of Child Health and Human Development (NICHD)
Bethesda, Maryland, United States, 20892-1103
Sponsors and Collaborators
Corcept Therapeutics
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
More Information

Additional Information:
Responsible Party: Corcept Therapeutics
ClinicalTrials.gov Identifier: NCT01925092     History of Changes
Other Study ID Numbers: 13-CH-0170
02811-12 ( Other Identifier: NICHD )
First Posted: August 19, 2013    Key Record Dates
Last Update Posted: August 4, 2014
Last Verified: July 2014

Keywords provided by Corcept Therapeutics:
Cushing's disease
Cushing's syndrome
Child/pediatric population

Additional relevant MeSH terms:
Pituitary ACTH Hypersecretion
ACTH-Secreting Pituitary Adenoma
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Pituitary Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Abortifacient Agents, Steroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptives, Oral, Synthetic
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Contraceptives, Postcoital, Synthetic
Contraceptives, Postcoital
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Luteolytic Agents